Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses the Myeloproliferative Disorders Research Consortium (MPD-RC 111), a clinical trial investigating single arm salvage therapy with pegylated interferon alfa-2a for patients with high risk polycythemia vera or high risk essential […]
MPD-RC 112 Clinical Trial for High Risk PV and ET Patients
Randomized Clinical Trial of Pegylated Interferon alfa-2a versus Hydroxyurea Ruben Mesa, M.D., hematologist at Mayo Clinic in Arizona, discusses MPD-RC 112, a randomized trial of pegylated interferon alfa-2a versus hydroxyurea therapy in the treatment of high risk polycythemia vera (PV) and high risk essential thrombocythemia (ET). Key Points: Why are we doing the Study? Top […]
Chronic Illness – A Physician’s View of Patients
Myeloproliferative Neoplasms are Chronic Illnesses Though rarely discussed in terms of Chronic Illness, MPNs most definitely fit the bill. Having a chronic illness, especially one that involves pain, fear and many unknowns, is concerning not only for patients but also the doctors who care for us. One doctor offers his perspective on what it is […]
PV Reporter featured on MPNforum
PV Reporter Gaining Recognition in the MPN World by David Wallace As you peruse this article, please keep in mind the publisher is not a “publicity-hound”, but getting recognized by the leading MPN publication is an occasion to celebrate! Three months running and PV Reporter has drawn several thousand readers with many new visitors flocking in […]
Jason Rappaport’s Polycythemia Vera Story
Publisher’s Introduction by David Wallace After experiencing my own “unpleasant….putting it kindly” tango with Poly, I transitioned through various stages of grief and have seen other patients travel a similar path over the last few years. Rarely have I seen a newly diagnosed patient jump in full bore with both feet, wet behind the ears […]
Positive Correlation seen between JAK2V617F allele burden and thrombotic mechanisms activation in Polycythemia Vera and Essential Thrombocythemia patients
JAK2V617F allele burden is associated with thrombotic mechanisms activation in patients with Polycythemia Vera and Essential Thrombocythemia Abstract The clinical courses of polycythemia vera (PV) and essential thrombocythemia (ET) are characterized by thrombohemorrhagic diathesis. Several groups have suggested an association between JAK2V617F mutation and thrombosis. We hypothesized a relationship between JAK2V617F allele burden, cellular activation […]
23andMe Ordered by the FDA to Halt Sales of Genetic Test
Google backed Genetic Test Maker 23andMe told to Halt Sales by the Food and Drug Administration (FDA) As most readers know, 23andMe offered genetic testing for free to further research for MPN patients. A noble gesture indeed. I readily participated and found the highly detailed report very thought provoking, but perhaps “missing the mark” in […]
The American Society of Hematology (ASH) Annual Meeting and Exposition 2013
2013 ASH Annual Meeting and Exposition- KEY ABSTRACTS for Myeloproliferative Neoplasms December 7-10, 2013 – Ernest N. Morial Convention Center, New Orleans, LA Myeloproliferative Neoplasms Absracts Frequent Mutations in the Calreticulin Gene CALR in Myeloproliferative Neoplasms The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients Increased Platelet Thrombus Formation Under Flow […]
Medical scientists in Melbourne invent novel approach worldwide to Cure Leukemia
Combo Blood Cancer Treatment Attacking JAK2 Protein – A Possible Approach to Curing Leukemia Australian medical scientists have discovered a new approach which is regarded as the landmark to kill blood cancer cells for treating a large number of aggressive adult and childhood leukemia, Melbourne’s Peter MacCallum Cancer Centre said via the Friday’s media release. The report […]
Living Well with Myeloproliferative Neoplasms
MPN town meeting Andrew Schorr from Patient Power -November, 23, 2013 – MD Anderson Cancer Center – Houston, TX Growing research is leading to a new understanding of Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). Excitement is building among experts about new treatment options which are shaping up […]
